Daily as of 3 Nov 16:00 ET
- Price
- between the two $12.18 vs 50 $12.31 / 200 $6.93
- Projection
- No cross projected
- Test
- No active test
- Last cross
- 🟨Golden cross 1 Jun 2026 · projected 30 bars out
ABCL | AbCellera BiologicsNASDAQHealthcareCommon stock golden cross and death cross projections, cross tests and history
$12.18
+$1.06 (+9.53%)
AbCellera Biologics (ABCL) is a NASDAQ-listed common stock that Cruxta has tracked for 50/200 crosses since 2022.
The 50 SMA has sat above the 200 on the daily since Jun 2026, with no cross projected inside the 30 bars Cruxta tracks. On both the daily and the 4-hour, price sits between the 50 and the 200; on the weekly it is above both.
Timeframe summary
Weekly as of 30 Oct 16:00 ET
- Price
- above both $12.27 vs 50 $6.30 / 200 $5.05
- Projection
- No cross projected
- Test
- No active test
- Last cross
- 🟨Golden cross week of 31 Aug 2026 · projected 21 bars out
4-hour as of 3 Nov 16:00 ET
- Price
- between the two $12.18 vs 50 $12.59 / 200 $9.80
- Projection
- No cross projected
- Test
- No active test
- Last cross
- 🟨Golden cross 24 Apr 2026 · projected 26 bars out
Cross history
| Crossed | Direction | Timeframe | Projected | Cross test |
|---|---|---|---|---|
| week of 31 Aug 2026 | 🟨Golden moderate | weekly | 21 bars out | Not tested |
| 1 Jun 2026 | 🟨Golden moderate | daily | 30 bars out | Not tested |
| 24 Apr 2026 | 🟨Golden | 4-hour | 26 bars out | Not tested |
| 14 Jan 2026 | 💀Death steep | daily | 23 bars out | Not tested |
| 21 Nov 2025 | 💀Death | 4-hour | 26 bars out | Not tested |
About ABCL
ExchangeNASDAQ
InstrumentCommon stock
Median $ volume, 60 d$53.6M
4-hour coverageYes, since Oct 2025
History on recordSince 2022
SectorHealthcare
Cap bandmid